The protein glycosylation inhibitor tunicamycin protected male BALBjc mice from tumor necrosis factor a-induced liver failure. Tunicamycin also inhibited. tumor necrosis factor-induced cell death in primary hepatocyte cultures with a median inhibitory concentration of 8 riM, but not in the tumor cell line WEHI 164 clone 13. Hepatocyte death in our culture system was characterized by DNA fragmentation and apoptotic changes. These two characteristic signs of programmed cell death were also inhibited by tunicamycin treatment. These data suggest that protein glycosylation is an early and causal event of tumor necrosis factor (TNF)-induced parenchymal cell death in the liver.
Introduction
Tumor necrosis factor (TNF) is a cytokine with a vast spectrum of physiological and pathophysiological functions characterized initially by its tumor-necrotizing and cachexia-inducing properties. TNF is released from tissue macrophages or various blood leukocytes during inflammatory reactions. At high systemic concentrations it may cause circulatory and multi organ failure in animals and man (Tracey and Cerami. 1993; Waage, 1992) . Hepatotoxicity due to TNF may become manifest in clinical systemic inflammatory response syndromes and also represents a major restriction of the chemotherapeutic use of the cytokine. In vitro, TNF was shown to induce programmed cell death in murine hepatocytes under the condition of transcriptional arrest. However, in these primary liver cell cultures intact translation was required for the induction of apoptosis by TNF (Leist et aI., 1994) .
Tunicamycin inhibits N-linked protein glycosylation by blocking the transfer of N-acetylglucosamine-lphosphate from UOP-N-acetylglucosamine to dolichyl phosphate (Elbein, 198 I) . It consists of variously acylated homo logs of a conserved uridine-containing trisaccharide structure (Duksin and Mahoney. 19iQ) . Tunicamycin does not directly affect the synthesis of the polypeptide chain of proteins. Attempts have been made to use the compound as an experimental chemotherapeutic agent. since it has been reported to be selectively cytotoxic towards transformed cell lines (Kohno et aI., 1979) . In the present study we describe the protective action of this antibiotic against TNF-induced cell death in untransformed murine hepatocytes in vitro and its protective properties against TNF-induced hepatotoxicity in mice.
Materials and methods

Reagents
Recombinant murine TNF-a was generously provided by Or. Adolf, Boehringer Institute (Vienna, Austria). Cell culture media were from Biochrom (Berlin, Germany). GaIN was purchased from Roth (Karlsruhe. Germany). Tunicamycin was from Boehringer (Mannheim, Germany), collagenase. actinomycin D and all other substances were purchased from Sigma (Oeisenhofen, Germany). First publ. in: European Journal of Pharmacology: Environmental Toxicology and Pharmacology Section 292 (1995), 2, pp. 201-204 Konstanzer 
Animal experiments
Male BALB/c mice (25 g) were from the internal animal breeding house, University of Konstanz. For cell preparations mice were fed ad libitum, whereas they were starved overnight for the in vivo experi~ ments. All animals received humane care in accordance with the recommendations of the Helsinki declaration and Germany's legal requirements.
At 8 a.m. animals were injected in the tail vein with TNF (3.3 p.g/kg in a volume of 300 p.l saline containing 1 % BSA). Liver damage was assessed by measuring plasma enzymes 8 h later according to Bergmeyer (1984) . Actinomycin D or tunicamycin were given intraperitoneally in a volume of 200 p.l saline, 2 min or 30 min, respectively, before TNF injection. Blood was sampled in heparin-coated syringes by cardiac puncture immediately after killing the animals by cervical dislocation.
Cell cultures
WEHI-164 clone 13 cells were used for the TNF toxicity determination essentially as described by Espevik and Nissen-Meyer (986). Hepatocytes were isolated by the two step collagenase perfusion method of rmuTNF-a (ng/ml) Seglen (1973) with a viability exceeding 80% according to the trypan blue exclusion method. Cells were plated in 200 p.l RPMI 1640 medium containing 10% newborn calf serum in 24-well plates at a number of 8 X 10"' hepatocytes per well. They were allowed to adhere to culture plates for 5 h before the medium was exchanged for RPMI 1640 medium without serum. Experiments were carried out in an incubator supplied with 5% CO z , 40% 0z and 55% Nz for the times indicated.
Cytotoxicity, chromatin condensation and DNA fragmentation
Lactate dehydrogenase was determined (Bergmeyer, 1984) in culture supernatants (S), and in the remaining cell monolayer (C) after lysis with Triton X-lOO. The percentage of lactate dehydrogenase release was calculated from the ratio of S/(S + C). DNA fragmentation was determined by agarose gel electrophoresis (WylIie. 1980) . Fluorescence microscopy was performed on an Axiovert 35, Carl Zeiss (Oberkochen, Germany) using hepatocytes fixed for 10 min in 3.7% formaldehyde and stained for 15 s with 8 p.g/ml bisbenzimide H33258. Riedel-de Haen (Seelze, Germany). 3. Results
Protection by tunicamycin against TNF-induced liver fa~lure in actinomycin D-sensitized mice
In order to extend our previous findings on the protection by inhibitors of protein synthesis against TNF-induced septic liver failure (Leist et aI., 1994) , we used the glycosylation inhibitor tunicamycin in order to examine whether glycoprotein synthesis is required for the manifestation of TNF-induced hepatotoxicity. The data in Table 1 show that actinomycin D /TNF-induced liver injury was significantly reduced in mice that had been pretreated with tunicamycin. Control experiments showed that actinomycin D, TNF or tunicamycin alone did not significantly affect the plasma enzyme activities measured 8 h after administration of these agents. All animals treated with actinomycin D /TNF died within 8 h, whereas no mortality was observed within this time span in mice pretreated with tunicamycin and then challenged with actinomycin D /TNF. These results suggest that an N-glycosylated protein is a necessary factor for TNF-induced liver failure in actinomycin D-pretreated mice.
Protection of murine hepatocytes from actinomycin D / TNF-induced programmed cell death by tllnicamycin
Next we examined whether tunicamycin acted in fact on the hepatocyte, i.e., the dominant target cell of TNF in this model of septic liver failure. Therefore primary liver cell cultures were preincubated with tunicamycin and actinomycin D for 30 min prior to the addition of TNF. We observed a significant and concentration-dependent protection of hepatocytes from TNF cytotoxicity (Fig. lA) with a median inhibitory concentration of 8 ± 2 nM for tunicamycin. The glycosylation inhibitor alone was not toxic towards hepatocytes at concentrations less than 5 ,uM. Thus, very low and non-toxic concentrations of tunicamycin were sufficient to protect actinomycin D-sensitized cultured hepatocytes from TNF-induced cell death. The attenuation of TNF toxicity due to the glycosylation inhibitor was not only observed after preincubation, but also when 500 nM tunicamycin was added within 4 h after TNF (reduction of toxicity by 50%). This means that TNF-inducible cytotoxicity is partially reversible following cytokine exposure. These findings are a further indication of the involvement of glycoproteins in actinomycin D /TNF toxicity. This conclusion is also corroborated by our observation that brefeldin A, an inhibitor of glycoprotein translocation from the endoplasmic reticulum to the' Golgi protected hepatocytes concentration-dependently from actinomycin D /TNF cytotoxicity (median inhibitory concentration: 178 ,uM).
We tested the influence of tunicamycin on TNF-induced toxicity in the murine fibrosarcoma cell line WEHI-164 clone 13. In this cell line TNF alone (2 ng/mn induced cell death associated with DNA fragmentation more rapidly than in hepatocytes. Only 3 h after the addition of TNF, viability was <ignificantiy reduced and DNA fragmentation was increased 22-fold compared to untreated control WEHI-l64 cells. Tunicamycin alone killed WEHI-164 cells with a median effective concentration of 170 ± 10 nM. In the presence of TNF at concentrations that caused 50-90q. cell death (32-4000 pg/mD we noticed an additive toxicity of tunicamycin rather than a protection. It may be conjectured that this, completely opposite, sensitivity towards tunicamycin of a transformed cell line represents a killing mechanism different from that in primary organ toxicity of TNF in naive cells, such as the hepatocyte.
Since TNF-induced cytotoxicity in actinomycin Dsensitized liver cells was shown to be preceded by DNA fragmentation and characterized by apoptotic changes (Leist et ai., 1994) , we examined whether tunicamycin treatment would interfere with these early events of cell death. We measured DNA fragmentation 10 h after addition of TNF, i.e., at a time point when no significant lactate dehydrogenase release in actinomycin D /TNF-treated cells was detectable. As demonstrated in Fig. lB , at this time point extensive DNA fragmentation, characterized by a 'ladder pattern' can be documented. This fragmentation was reduced almost to control levels in cells preincubated in the presence of tunicamycin. These findings indicate that tunicamycin-sensitive processes are likely to be involved in early apoptotic changes leading to cell death. The number of hepatocytes with chromatin condensation was quantitated 14 h after the addition of TNF (lOO ng/mn. On staining with bisbenzimide H-33258 we observed that the percentage of apoptotic nuclei detected in actinomycin D-sensitized hepatocytes (actinomycin D: 12 ± 5%) treated with TNF (actinomycin D/TNF: 40 ± 8%) was reduced significantly by pretreatment with 500 JLM tunicamycin (actinomycin D/TNF'+ tunicamycin: 20 ± 6%). Thus in addition to the inhibition of the early biochemical event, i.e., DNA fragmentation and the late manifestation of toxicity, i.e., lactate dehydrogenase release, tunicamycin also prevented the morphological changes associated with TNF-induced programmed hepatocyte death.
Discussion
In rodent models of inflammation, transcriptional inhibitors such as D-galactosamine or actinomycin D have been commonly used as sensitizers towards direct or indirect TNF toxicity (Lehmann et aI., 1987; Wallach et aI., 1988; Wendel, 1990) . The pathomechanism induced by TNF involves apoptosis of hepatic parenchymal cells (Leist et aI., 1994) . Among a large panel of compounds that we screened for the property of preventing cytokine-induced liver cell death, the by far most potent protective agent was the uridyl antibiotic tunicamycin. It did not only prevent cytotoxicity, apoptotic changes and DNA fragmentation in hepatocyte primary cultures exposed to TNF, but also protected mice from TNF-induced hepatic failure. At the nanomolar concentrations of tunicamycin used in this study ribosomal polypeptide synthesis is not significantly affected. However, dolichyl-dependent protein glycosylation is inhibited and typical glycoproteins such as a z-macroglobulin, ceruloplasmin or a I-protease inhibitor are no longer secreted from liver cells (Yeo et aI., 1989) . This potent inhibition of hepatocyte apoptosis by tunicamycin indicates that a de novo synthesized glycoprotein is involved in TNF-induced programmed liver cell death.
With hepatocytes treated with tunicamycin only, we observed neither an increased lactate dehydrogenase release, nor a reduced formazan formation from tetrazolium salts nor any morphological signs of tun icamycin-induced cytotoxicity. In contrast to these findings, the antibiotic was toxic to murine fibrosarcoma cells; this is in agreement with previous findings that tunicamycin selectively damages transformed cell lines (Kohno et aI., 1979) . On the basis of such findings it may be speculated that cotreatment with tunicamycin or related substances may represent a means of increasing the selectivity of TNF for tumor cells.
